Indeed, in our study, the pCR rate in patients with HER2-positive breast cancer who received neoadjuvant chemotherapy with trastuzumab was 50% (27 out of 54), which was much higher than that for the study group as a whole (20%, 88 out of 449). This evidence concerns the gene ERBB2 and breast cancer.